z-logo
open-access-imgOpen Access
Locally advanced non-small cell lung cancer, pretreatment prognostic factors: Disease stage, tumor histopathological characteristics, the patient-related factors
Author(s) -
Ljiljana Vasić
Publication year - 2007
Publication title -
archive of oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.104
H-Index - 13
eISSN - 1450-9520
pISSN - 0354-7310
DOI - 10.2298/aoo0702019v
Subject(s) - medicine , stage (stratigraphy) , lung cancer , disease , cancer , performance status , oncology , diabetes mellitus , paleontology , biology , endocrinology
Background: The existing tumor-node-metastasis staging system ignores numerous clinical, therapeutic, and biological characteristics of lung cancer and psychomotor condition of a patient because it is based on the anatomic extent of disease. Therefore, there is a possibility of inadequate choice of therapy for any individual patient. Based on the disease stage, histopathological characteristics of the tumor and the patient-related factors (sex, age, Karnofsky status, accompanying diseases) the outcome of the disease can be predicted in patients with inoperable and unresectable non-small lung cancer. Methods: This report is a prospective clinical study that included patients with histopathological verified non-small cell lung cancer, followed up for a six-month period, from the beginning of the treatment. The following data were recorded: sex, age, histological cancer type, stage, Karnofsky status, and comorbid diseases. Results: The study showed planocellular carcinoma was more dominant among men than among women and that and at the diagnosis, most patients were in IIIb or IV stage. There was a decrease in psychomotor status of patients. The length of survival depended on Karnofsky index (p= 0.000), comorbidities - chronic myocardiopathy (p= 0.001), diabetes mellitus type 2 (p =0.007), myocardial infraction (p= 0.005), and the stage of the disease (p= 0.001) Conclusion: Psychomotor status of a patient, comborid diseases, and the stage of disease are the factors that determine patient’s tolerance to oncology treatment

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom